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ABSTRACT Lymphangiogenesis, the formation of
new lymphatic vessels from preexisting ones, is an
important biological process associated with diverse
pathologies, such as metastatic dissemination and graft
rejection. In addition, lymphatic hypoplasia character-
izes lymphedema, usually a progressive and lifelong
condition for which no curative treatment exists. Much
progress has been made in recent years in identifying
molecules specifically expressed on lymphatic vessels
and in the setting up of in vitro and in vivo models of
lymphangiogenesis. These new tools rapidly provided
an abundance of information on the mechanisms un-
derlying lymphatic development and the progression of
diseases associated with lymphatic dysfunction. In this
review, we describe the common in vitro and in vivo
models of lymphangiogenesis that have proven suit-
able for investigating lymphatic biology and the
interactions occurring between lymphatic vessels and
other cells, such as immune cells and cancer cells.
Their rationales and limitations are discussed and
illustrated by the most informative findings obtained
with them.—Bruye`re, F., Noe¨l, A. Lymphangiogen-
esis: in vitro and in vivo models. FASEB J. 24, 000 – 000
(2010). www.fasebj.org
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The lymphatic vascular system plays a key role in
tissue–fluid homeostasis, as a tissue-drainage system,
and contributes to the immunosurveillance by provid-
ing a route for migrating cells. The terminal vessels of
this network collect extravasated fluids, macromole-
cules, lymphocytes, and antigen-presenting cells from
the tissues and return them to the blood circulation via
larger collecting lymphatic vessels and the thoracic
duct (1). Lymphatics are also essential for the absorp-
tion of long-chain dietary triglycerides and lypophilic
compounds released in the intestine in the form of
chylomicrons. Impairment of the lymphatic-transport
capacity because of abnormal vessel development or
damaged vessels causes stagnation of water and pro-
teins in the interstitium and leads to lymphedema.
Lymphangiogenesis, the formation of new lymphatic
vessels, is associated with several pathological condi-
tions, such as chronic inflammation (Crohn’s disease,
psoriasis) (2–4), renal or corneal graft rejection (5, 6),
malignancies, and metastatic dissemination (1, 7).
The structure of the lymphatic system, the lymphatic
endothelial cell (LEC) markers, and the molecular
mechanisms underlying lymphatic system development
and function in pathologies have been largely reviewed
(1, 8, 9) and are beyond the scope of this review. In
contrast to angiogenesis research, lymphatic vessel re-
search was long hampered by the lack of valuable
markers and experimental models. Lymphatic system
identification in small animals, transgenic mouse gen-
eration, tool development and validation, and recent
in vitro models of 2- and 3-dimensional (2-D and 3-D)
endothelial cell culture pave the way for a new area in
the field of lymphangiogenesis. Obviously, no single
model is able to elucidate the entire process of lym-
phangiogenesis associated with various pathological
situations. Although in vivo assays are obviously more
relevant than in vitro assays, they are time consuming
and expensive, and the part played by the inflammatory
response in them renders interpretation of the results
difficult. Therefore, in vitro models, under more con-
trolled and defined conditions, are complementary to
in vivo experiments.
The present review aims to help researchers in their
experimental exploration of the lymphatic system. We
describe the common in vitro and in vivo models of
lymphangiogenesis that have proven valuable for study-
ing this complex biological process. The different ex-
perimental systems are presented and discussed in
order of increasing complexity, starting from primary
monolayer cell cultures and progressing to in vivo
studies. We critically examine their advantages and
limitations and illustrate them with the pertinent infor-
mation derived from them.
LEC CULTURES
Isolation methods
LECs are isolated from collecting vessels, such as the
lymphatic thoracic duct, or lymphatic capillaries, pri-
marily in dermal tissue. Gnepp et al. (10) isolated LECs
from canine and human lymphatic thoracic duct by
enzymatic digestion. Later on, this method was applied
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to bovine, porcine, and rat species, and has generated
cells with morphological features consistent with those
of intact lymphatic endothelia (11–16). However, be-
cause that enzymatic method yielded barely enough
cells for molecular analyses (17), especially from ro-
dents, LECs were immortalized by using tsA58-trans-
genic rats harboring a simian virus 40 (SV40)-mutant
temperature-sensitive large T-antigen gene (18). To
isolate LECs from lymphatic capillaries, adult or new-
born human foreskin is the most widely used source.
Lacking known specific markers, LECs and blood
endothelial cells (BECs) were initially separated by
excluding BECs through the isolation of a nonvascular-
ized area of skin (19). That approach led to the
identification of several lymphatic cell surface markers
(20). LEC selection is now obtained by immunopurifi-
cation, either with fluorescence-activated cell sorting
(FACS) or magnetic beads (21–25). CD31, the hyalu-
ronan-binding protein, lymphatic vessel endothelial
receptor-1 (Lyve-1), and podoplanin are antigens
widely used for LEC isolation.
To overcome the limited growth potential of primary
cells, cell populations can be transformed with the
human telomerase reverse transcriptase (hTERT; hu-
man dermal LECs) and achieve an extended life span
(26). These LECs were molecularly characterized by
gene arrays under physiological conditions, treatment
with vascular endothelial growth factor-C (VEGF-C), or
after transfection with the transcription factor Pros-
pero-related homeobox 1 gene (prox-1) (22, 23, 27, 28).
Dermal LEC isolation has the advantage of providing
many more cells than enzymatic digestion of the tho-
racic duct. However, the immunoselection methods
often give rise to biased results in gene- and protein-
expression profiles, depending on the antibodies
used. Moreover, both methods (using the lymphatic
thoracic duct or the dermis) isolate cells that need to
be cultured in supplemented medium, and close
attention must be paid to the growth factors added.
Indeed, LECs can be contaminated by BECs express-
ing lymphatic markers, as was reported for interleu-
kin-3-treated BECs, which express two lymphatic an-
tigens (Prox-1 and podoplanin) (29, 30). Inversely,
BEC cultures are often contaminated with LECs or
differentiate into LECs (31).
Recently, different LECs were isolated from the
microlymphatic vessels in various tissues. A rat mesen-
teric LEC line (RMLEC) was established and character-
ized according to its morphology, phenotypic stability,
lymphatic marker presence, cell-adhesion molecule ex-
pression (32), molecular profile, and proliferative re-
sponse (33). Yamaguchi et al. (34) reported the isola-
tion and long-term culture of organ-specific LECs
issued from transgenic mice expressing the SV40 tsA58
large-T antigen. Little information is available about
the different morphological and functional properties
of LECs issued from microlymphatic (initial) and ma-
crolymphatic (collecting) vessels. Kawai et al. (35) re-
ported heterogeneous immunohistochemical, genomic,
and biological properties of initial and collecting LECs
based on their comparison of human newborn dermal
LECs and LECs derived from afferent collecting lymph
vessels of the sentinel lymph nodes of breast cancer
patients. However, further studies are needed to estab-
lish and clarify that suspected heterogeneity. A LEC-
selection procedure avoiding the use of antibodies is
based on LEC differentiation from embryonic stem
cells (36), which can be achieved by adding growth
factors (VEGF-C and VEGF-A) or by coculturing cells
with OP9 mouse stromal cells (37–39).
LECs for cultures were also isolated from lym-
phangiomas, which are lesions induced by incom-
plete Freund’s adjuvant injection into the peritoneal
cavity of mice (40) or rats (41). Lymphatic vessels
from this lesion are mechanically disrupted, and LEC
is enzymatically isolated before seeding onto a 2-D
substrate (42, 43) or being embedded in a fibrin gel
for 3-D cultures (44). Lymphangioma-derived cells
were used to generate two monoclonal antibodies
enabling LECs and BECs to be distinguished (45).
Once again, cell immortalization was achieved by
isolating cells from SV40 tsA58-transgenic mice and
inducing their large-T–antigen expression with inter-
feron- (46). This system has the advantage of being
applicable to knockout mice and thus to allow the
comparison of LECs from animals deficient or not
for one or another gene.
All these mammal LEC-isolation models have their
own advantages and disadvantages. When isolated
from nontransformed animals, only a limited num-
ber of cells are available, and immortalization can
change their features. Moreover, the LEC cultures
can suffer from dedifferentiation phenomena. Two
elegant studies compared the gene-expression pro-
files of LECs and BECs directly isolated from tissues,
with or without expansion in cell culture (31, 47).
Transcriptional analyses of ex vivo and in vitro 2-D
LEC and BEC cultures indicated that cell culture
introduces substantial changes in gene expression.
LECs do not always retain all lymphatic properties
in vitro, for instance, the Lyve-1 expression or CCL21
chemokine production (48). Interestingly, in such
culture systems, the inflammatory cytokines such as
tumor necrosis factor (TNF-) regulate the produc-
tion of Lyve-1, chemokines, and adhesion molecules,
including VCAM, ICAM, and E-selectin (48 –50).
2-D LEC cultures
In most assays, LECs are seeded as monolayers on
culture plates or onto the surface of matrix-coated
plates. Such 2-D cultures are suitable to evaluate the
effects of putative lymphangiogenic stimulators or in-
hibitors on specific LEC properties. While none of the
2-D cultures can undergo all steps of lymphatic vessel
formation, all culture systems contribute to analyzing
each step individually, using various assays of cell
activities (e.g., gene expression profiling), cell prolifer-
ation, apoptosis, adhesion, migration (wound scratch
assay, boyden chamber assay), and morphogenesis (tu-
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bulogenesis) (Fig. 1). These assays are reviewed in the
context of angiogenesis research (51) and illustrated in
a recent study on the lymphangiogenic effect of soma-
totropin (52) or Galectin-8 (53). LEC monolayer cul-
tures have also proven suitable to explore the molecu-
lar mechanisms of transmigration across LECs (49).
They have the advantages of achieving defined experi-
mental conditions, using a relatively uniform endothe-
lial cell population, and being easily quantifiable. With
these models, studies on an individual gene or protein
are applicable by up-regulating them with recombinant
molecules or down-regulating them through a small
interfering RNA approach, for instance.
3-D LEC cultures
LECs differentiated from human embryonic stem cells
can be cultured easily as 3-D structures called embryoid
bodies in 3-D matrix. These embryonic spheroids
grown in a gel can then be grafted with fibroblasts into
mice and should adhere to the mouse circulation
under appropriate conditions (54, 55). These sphe-
roids offer the opportunity to study the formation of
the initial lymphatic system during embryonic stages,
but their pertinence to the biology of mature lymphatic
vessels remains to be proven. To mimic the in vivo
context in which LECs are subjected to interstitial flow
from the extracellular matrix, Ng et al. (56) improved
capillary morphogenesis by introducing an artificial
flow. Moreover, in the presence of matrix-binding
VEGF, flow induced local VEGF gradients, which fur-
ther improved capillarogenesis (57).
A novel model mimicking the formation of entire
lymphatic capillaries was recently reported (58, 59).
Small fragments of mouse lymphatic thoracic duct were
embedded in a collagen gel and produced outgrowths
of lymphatic vessels with a lumen. This model is suitable
for screening lymphangiogenic factors but also for
phenotyping transgenic mice. For example, this lym-
phatic-ring assay helped identify matrix metallopro-
tease-2 (MMP-2) as a key regulator of LEC sprouting
(58). Such 3-D cultures of LECs from rat lymphatic
ducts were described previously, but they had been
contaminated by other vascular cell types (60). Indeed,
we confirmed the cell population heterogeneity ob-
tained with rat lymphatic thoracic duct (unpublished
observations). In sharp contrast, when mouse lymphat-
ics were used, sprouting cells were exclusively LECs
(58). The advantages of the lymphatic-ring assay are
that LECs are not preselected by immunoisolation
and/or passaging; inflammatory complications are
avoided, offering the possibility to investigate direct
effects on LECs; and it is an accessible method to
examine LEC biology in transgenic knockout or
knock-in mice.
While 2-D cultures address separately the different
steps of the vessel formation (see above), 3-D cultures
bridge the gap between in vitro and in vivo assays and
are available to follow the sprouting process and LEC
morphogenesis (Fig. 1). The 3-D cultures in complex
matrices of embryonic bodies (37) or LECs with inter-
stitial flow (61) allow tube formation and are suitable
for examining the formation of a complex plexus,
similar to that observed during embryogenesis. The
lymphatic-ring assay (58) appears as a potent tool for
the study of pathological lymphangiogenesis, defined
as the abnormal formation of new lymphatic vessels
from preexisting ones.
Organotypic models
Ex vivo studies on excised vessels can also be under-
taken to analyze functional features of larger lymphatic
vessels. For example, the Rho–Rho kinase pathway was
shown to be involved in lymphangiogenic myogenic
tone (62). The pump activity was investigated on iliac
afferent lymph vessels transferred into an organ cham-
ber, where the duct was mounted on pipettes to ensure
its perfusion. In this system, vessel permeability was
evaluated through the endothelial barrier (63). Simi-
larly, the lymphatic flow pathway of fluorescent sub-
stances was visualized in isolated rat lymph nodes (64)
or the lymphatic thoracic duct (65, 66). Lymph nodes
were also reconstructed in vitro by using a bioreactor
that allows self-assembly of human lymphatic tissues,
with reestablishment of immune-cell traffic (67). Such
scaffold-engineering models also exist for studying an-
giogenesis; seeding endothelial cells in matrix gels that
have open channels spanning the gels forms tubes.
Over time, these endothelial tubes developed func-
tional behaviors typical of microvessels in vivo, e.g.,
functioning as a barrier and serving as a leukocyte-
adhesion site (68, 69). Similarly, such systems are well
engineered to study the physiological functions of
larger lymphatic vessels, especially lymph pumping,
which is highly specific to vessels with a muscle-cell
layer (70).
IN VIVO ASSESSMENT OF LYMPHATIC VESSELS
Several models of lymphangiogenesis are available (Fig. 2).
Most were designed to investigate this process in a partic-
ular physiological or pathological condition. Here, we
consider the models according to their relevance in
various situations: physiological processes, embryogenesis,
and pathological lymphangiogenesis associated with ge-
netic disorders, edema, or cancer. Particular attention has
been paid to the tools used to visualize the lymphatic
vessels.
Visualization of the lymphatic tree under
physiological conditions
Lymphatic vessels are present in almost every vertebrate
organ other than avascular tissues, such as the epider-
mis, cartilage, and cornea, and some vascularized tis-
sues, such as the brain, bone marrow, and retina (71).
Immunohistochemical labeling of specific LEC anti-
gens is still the most widely used method to identify
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Figure 1. The different in vitro assays to unravel lymphangiogenesis. The level of complexity increases from 2-D cultures of LECs
to lymphatic organotypic cultures. The 2-D cultures of LECs isolated from the different sources indicated in the text are
powerful tools to study individually the different steps of lymphangiogenesis, i.e., LEC proliferation, migration, invasion and
morphogenesis (tubulogenesis). Cell morphogenesis can be improved under a continuous flow. The 3-D cultures, including the
embryonic body and the lymphatic ring assay, are more appropriate models to dissect the mechanisms underlying the whole
process of vasculogenesis or lymphangiogenesis. The perfusion of lymphatic organs or vessels are suitable for investigating vessel
functionality.
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lymphatics. Among specific lymphatic markers recently
reviewed (20), Lyve-1, Prox-1, podoplanin, and VEGF-
receptor-3 (VEGFR-3) are the most frequent molecules
examined. Under physiological conditions, lymphatic
vessel densities and morphologies are routinely as-
sessed after immunolabeling of tissue sections of nor-
mal skin, gut, intestine, trachea, and ears (58, 72–75).
As a complementary approach, lymphatic vessel func-
tionality is assessed by exploiting the capacity of lymphat-
ics to absorb fluids and molecules according to hydro-
static and oncotic pressure gradients. After subcutaneous
injection, a macromolecule transits into the lymphatic
network before reaching the blood circulation. The lym-
phatic vessels and lymph nodes drain Evans blue stain, a
high-molecular-weight protein, within 15 min (76). Evans
blue staining can be used to visualize lymph nodes and
the thoracic duct in healthy mice (58), as well as in
pathological lymphangiogenesis (74, 77). Similarly, fluo-
rescence microlymphangiography (FITC–dextran) (78),
can be used in vivo and is suitable to visualize the
lymphatic tail network, for instance (79, 80). Lymphatic
ferritin incorporation allows subsequent histochemical
staining with Prussian blue (potassium ferrocyanide and
HCl) detection of FeIII (81). Other more complex and
expensive approaches include microlymphographic pro-
cedures, such as radiolymphangiography scanning (82)
or magnetic resonance lymphangiography (83). The in-
jection of two different fluorescent quantum dots
(nanometer-size particles) into two different animal
loci (84, 85) allows the simultaneous analysis of the
flows of two different lymphatic vessels. A new ap-
proach uses hyaluronic acid-conjugated quantum
dots to visualize lymphangiogenesis in real time
in vivo (86). Finally, the function of intestinal lym-
phatic vessels that transport absorbed fat to the liver
can be exploited to observe lipid absorption using
fluorochrome-coupled molecules (87, 88).
Embryonic lymphangiogenesis
The origin of lymphatic vessels is still controversial and
the object of debate. The initial theory of lymphatic
vessel origin, advanced by Florence Sabin and based on
ink-injection experiments in pigs (89), supports the
concept of centrifugal sprouting from the primary
Figure 2. In vivo models to study lym-
phangiogenesis and their close link with
inflammation. Lymphangiogenesis and
inflammation are two closely related
processes. Lymphangiogenesis contrib-
utes to inflammation resorption, and
vice versa, inflammatory cells influence lymphangiogenesis through the secretion of stimulatory factors such as, at least, VEGF-C. Moreover,
macrophages were reported to incorporate into the lymphatic vessel wall. The inflammatory cell recruitment in vivo has to be
considered carefully in interpreting the results. The lymphatic network formed under physiological conditions (in adults or
during embryogenesis) is independent of inflammation and can be assessed on tissue sections of, for instance, normal skin, gut,
intestine, trachea and ears, using transgenic mice or small animals (Xenopus and zebrafish). In contrast, lymphangiogenesis
induced in various pathological conditions is influenced by the presence of the inflammatory reaction. In these systems, one
must pay attention to the putative indirect effects of inflammatory cells on lymphangiogenesis.
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lymph sacs that arise from embryonic veins (90). Inves-
tigation of pre- or postnatal lymphangiogenesis has
primarily been based on the use of transgenic mice. For
example, the homeobox gene prox-1 is the main factor
known to make part of the jugular vein commit to
lymphatic development. Notably, Prox-1–deficient
mice do not have a lymphatic network (91). Similar
approaches demonstrated the crucial role of VEGF-C,
among other factors, in the sprouting of the first
lymphatic vessels from embryonic veins (92). Moreover,
the injection of recombinant adenovirus-encoded solu-
ble VEGFR-3–Ig into newborn mice on d 1–7 led to the
almost complete absence of lymphatic vessels (71).
Other lymphatic-gene mouse models are available, such
as mice deficient for Net (93), podoplanin (94), neu-
ropillin-2 (NRP-2) (95), angiopoietin-2 (Ang2) (96),
integrin-9 (97), p85 subunit of PI3K (98), intracellular
signaling protein Slp76, trisomy-16 (99), or vascular
endothelial zinc finger-1 (Vezf1) (100) (reviewed in ref.
101). Another theory for the lymphatic vessel forma-
tion refers to a mesodermal origin of LECs and is
sometimes combined with the vessel-sprouting origin
(102). The avian chorioallantoic membrane (CAM) was
used to support this concept of progenitor cell recruit-
ment and to demonstrate its dependence to VEGF-C
(103, 104).
New models in small animals were recently validated
for the study of lymphangiogenesis. The Xenopus laevis
tadpole was first described as having a lymphatic system
only in 2005 (105), and the adult frog is known to have
a lymphatic network with beating lymphatic hearts
(106). Studies on the lymphatic network of this am-
phibian demonstrated that this system is dependent on
the lymphangiogenic factors Prox-1 and VEGF-C, and
showed the critical role of VEGFR-3 in embryonic
lymphatic development and functions (105, 107). Kalin
et al. (108) used this model for a chemical library
screening approach, identifying 32 active compounds
interfering with blood and/or lymphatic development.
A year later, two independent groups reported the
presence of a lymphatic system in zebrafish (109, 110).
Zebrafish lymphatic vessels have characteristics similar
to those of other species: conserved anatomy, morpho-
logical features (i.e., anchoring filaments), conserved
gene expression (Prox-1, VEGF-C, NRP-2, Ang2), and
functional features (111). The role of VEGF-D in this
vasculature was examined and compared to its role in
blood-vessel angiogenesis (112). These small-animal
models are valuable to dissect the molecular mecha-
nisms underlying lymphatic vessel development.
Lymphedemas and lymphangiomas
Lymphedema is defined as tissue swelling, usually the
skin, caused by the failure of proper lymphatic
drainage that can be due to lymphatic hypoplasia or
malformation, impaired lymphatic transport func-
tion, or obstruction of lymph flow (113, 114). Pri-
mary lymphedemas result from genetic defects,
whereas secondary (acquired) lymphedemas are
mainly caused by surgical removal or irradiation of
lymph nodes, or by chronic infection (filariasis).
Once again, the generation of transgenic animals
targeting specific genes represents a potent tool to
study hereditary lymphedemas.
A model of human Milroy’s disease, chy-mutant
mice are characterized by chylous ascites accumula-
tion in their abdomens and express a heterozygous
inactivating point mutation in vegfr-3 (115). Crossing
those chy mutants with K14–vegf-C156S mice, which
overexpress the VegfR-3–specific ligand Vegf-C156S,
led to the restoration of lymphatic function in the
double-transgenic offspring (115). In such experi-
ments, the lymphatic network and its functions were
visualized either by fluorescence microscopy of the
ears after intradermal injection of FITC– dextran or
after Evans blue injection into deeper lymphatic
vessels. Transcapillary fluid-balance parameters can
also be assessed (116).
Transgenic mouse models with features of human
lymphedema also generate transgenic overexpres-
sion of the soluble form of the Vegf-C or Vegf-D
receptor (sVegfR-3) following the keratin 14 gene
promoter that achieved regression of the lymphatic
vessels in several organs, i.e., the skin, and lymphed-
ema (73). Forkhead box C2 (foxc2)-haploinsufficient
mice have defective lymphatic recruitment of peri-
cytes, the mechanism underlying the pathogenesis of
the lymphedema-distichiasis syndrome (74, 117). In-
triguingly, lymphatic vessels could be regenerated in these
lymphatic system-defective mice by using adenovirus- or
adenovirus-associated virus (AAV)-mediated transduction
of vegf-C or its vegfR-3–specific point-mutant form (vegf-
C156S) (118, 119). Mice deficient in podoplanin (94),
Net (93), integrin-9 (97), Vezf1 (100), Chy-3 (120), or
with trisomy-16 (99) or heterozygous vegf-C (121), also
suffer from edema (reviewed in refs. 101, 113).
Secondary lymphedemas can be experimentally in-
duced in several ways. Some models ligate or cauterize
deeper lymphatic trunks (79, 122, 123), where lym-
phatic vessel formation is then initiated along preestab-
lished routes of fluid flow. Fluid channels form within
the extracellular matrix, and then LECs migrate along
these channels and organize to form a functional
lymphatic network (124). In this system, hepatocyte
growth factor (HGF) expression, induced by intramus-
cular plasmid injection, reduces lymphedema by pro-
moting lymphangiogenesis (125). The lymphatic ves-
sels are detected by several methods: fluorescence
microlymphangiography with FITC-conjugated dextran
(124, 126) or tetramethylrhodamine-conjugated dex-
tran (127, 128), lymphoscintigraphy using 99mTc–sulfur
colloid (123), or gadolinium-enhanced indirect mag-
netic resonance lymphangiography (83). In this model,
in vivo bioluminescence imaging could visualize the
traffic of immune cells from a transgenic mouse ex-
pressing the firefly luc under the control of the -actin
promoter (123). Similarly, experimental lymphedema
was induced in rabbit ears (129–131) and reversed by
supplying VEGF-C to the ear (132, 133). Lymphedema
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could also be induced in rodents (rat or rabbit) by
surgical removal of a groin lymph node, followed or not
by regional irradiation (134–137). Lymphatic vessels
were detected by scintigraphy, magnetic resonance
imaging, protein refractometry or plain X-rays.
Lymphangiomas are benign malformations of the
lymphatic system (138). They can be induced in mice
(40) or rats (41) by injecting Freund’s adjuvant. This
induction, initially performed on a mouse’s ear (139,
140), was first devised to isolate LECs, as mentioned
above. It was also applied to challenge transgenic mice
and evaluate the effect of a gene deficiency on the
lymphangiogenic response (58, 88). However, it must
be kept in mind that lymphangioma is accompanied by
inflammation, which can bias the evaluation of lym-
phatic vessels.
Induced lymphangiogenesis
The wound-healing process is a complex cascade of
events that relies on several mechanisms, including
inflammation, angiogenesis, and lymphangiogenesis,
which is enhanced by the injection of VEGF-C or
VEGF-A (141, 142). Lymphatic vessels appear in the
wound concurrently with blood vessels but regress
earlier (143). Cicatrization was induced either on su-
perficial areas, such as skin (141, 142), or on localized
deeper loci requiring interruption of the popliteal or
axillary prenodal lymphatic collector vessel (144). The
removal of a circumferential band of the skin from the
midpoint of the mouse’s tail is a wound-healing model
in which lymphangiogenesis can be readily studied
(126, 145).
Under physiological conditions, the cornea is devoid
of lymphatics (146, 147). Corneal lymphangiogenesis
was observed during wound healing after thermal cau-
terization (148), suturing (149), or alkali injuries (150).
Lymphatic vessels were recruited from the corneal
limbus. Once again, this lymphangiogenic process ap-
peared to be dependent on the VEGF-C–VEGFR-3
pathway and could be fully inhibited by a blocking
antibody raised against the receptor without affecting
angiogenesis (150, 151). It is worth noting that age-
related changes in corneal lymphangiogenesis have
been reported: Young mice had better lymphatic re-
sponses than older mice (152). The pertinence of this
model is obvious in the context of inflammation and
graft-rejection studies (148, 153, 154). Furthermore,
the lack of vasculature within cornea was also exploited
by grafting pellets releasing putative lymphangiogenic
factors. Various growth factors [e.g., fibroblast growth
factor-2 (FGF-2), platelet-derived growth factor (PDGF),
HGF, Ang1] were implanted individually in a corneal
micropocket and were shown to enhance lymphangio-
genesis (155–158).
Infection-induced lymphangiogenesis was assessed
after infecting mice with Mycoplasma pulmonis, which
led to inflammatory cell influx, angiogenesis, mucosal
edema, epithelial changes, and fibrosis. In this model,
lymphangiogenesis persisted in the airway mucosa,
even after the resolution of inflammation and blood-
vessel remodeling. This lymphangiogenesis appeared
to be driven by VEGF-C and VEGF-D released from
inflammatory cells (72). Similar effects were observed
in a model of allergic airway inflammation induced by
ovalbumin sensitization and challenge. In this system,
the EphrinB2 implication was highlighted in lymphatic
and blood vessel development (159).
Oxazolone-induced delayed-type hypersensitivity re-
action in mouse ears triggers lymphatic vessel prolifer-
ation and enlargement, which might contribute to
stronger inflammatory responses (4). These inflamma-
tory tissues closely resemble human psoriasis, and
VEGF-A increased lymphatic recruitment to this lesion
and the draining lymph nodes (4, 160).
Ultraviolet-B irradiation of the skin resulted in prom-
inent lymphatic vessel enlargement (161). These en-
larged lymphatics were functionally impaired and more
permeable and could be restored by the activation of
the VEGFR-3 pathway through VEGF-C (162). Intrigu-
ingly, an inhibitor of the nitric oxide receptor (soluble
guanylate cyclase) prevented irradiation-induced lym-
phatic vessel enlargement, skin inflammation, and
edema (163).
Artificial lymph-node-like tissues could be generated
by implanting biocompatible scaffolds with embedded
stromal cells into the renal subcapsular spaces of mice
(164). Like natural lymph nodes, they contained T, B,
and dendritic cells and lymph vessels. Moreover, ger-
minal centers developed in these artificial lymph nodes
following immunization, as in intact lymphoid tissue
organoids (165). This model is suitable to examine
lymphangiogenesis inside lymph nodes, a process asso-
ciated with pathological conditions, such as cancer
dissemination (166, 167).
It is worth noting that all models cited here are
associated with inflammation, and particular attention
must be paid to the indirect effects that inflammatory
factors could exert on lymphangiogenesis. For exam-
ple, VEGF-A stimulates lymphangiogenesis in the cor-
neal neovascularization assay through the recruitment
and activation of macrophages, which are known to
produce VEGF-C in this system too (149, 168).
Cancer lymphangiogenesis
Lymphatic metastases are well documented, but the
understanding of lymphatic tumor dissemination is
currently controversial. It is not clear yet whether
tumor cells induce an active lymphangiogenesis, pro-
mote vessel hyperplasia, or passively enter the lym-
phatic circulation to drive tumor invasion into lymphat-
ics (for reviews, see refs. 7, 169, 170). Several cancer
models have aimed to address this important issue
(113). Lymphangiogenesis is studied intensely in breast
cancer or melanoma because lymphatic metastases
often occur in patients with these malignancies. Carci-
noma progression and lymphangiogenesis were as-
sessed in an orthotopic mammary-tumor model using
either MCF-7 or MDA-MB-435 cells overexpressing
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VEGF-C (171–174) or 293EBNA cells overexpressing
VEGF-D (175). VEGF-C expression induced more lym-
phatic vessel invasion inside the tumor and increased
the number of metastases that were thereby inhibited
by sVEGFR-3 or a kinase inhibitor. Lymphatic vessel
functionality was revealed by Evans blue drainage.
Xenotransplantations of different types of cancer-cell
lines, e.g., fibrosarcoma cells (176) or colorectal cancer
cells (177, 178), into orthotopic sites corroborated the
importance of VEGF-C-mediated lymphangiogenesis in
facilitating tumor spread. Indeed, subcutaneous injec-
tions of lung cancer (179), melanoma (176), or other
tumor cells (77) into immunocompetent rats confirmed
the involvement of the VEGF-C–VEGFR-3 pathway in tu-
mor-induced lymphangiogenesis and metastatic spread.
Moreover, vector-based expression of small-interfering
RNA targeting VEGF-C and/or VEGF-A limited tumor
lymphangiogenesis and reduced lymph node and lung
metastases in a syngeneic model of mammary cancers
(180). In addition, a complex dialogue between lym-
phatics and tumor cells was pinpointed. Chemotaxis for
tumor cells can be induced by LECs through laminin-
421 (181). Inversely, tumor cells can attract LECs
through, at least, angiopoietin-1 (182). Tumor cell trans-
plantation is also applicable onto the avian chorioallan-
toic membrane (CAM) for studying lymphangiogenesis
(183, 184).
The use of syngeneic rat or mouse models has the
great advantages of not using immunodeficient mice
and taking into account the entire inflammatory re-
sponse. Tumor lymphangiogenesis and lymph-node
metastases were studied in the chemically induced skin
carcinogenesis model of K14-vegf-C transgenic mice.
Notably, lymphangiogenesis was induced in the senti-
nel lymph node by Vegf-C release and it promoted
cancer metastasis beyond the sentinel lymph nodes
(166, 167). These data support the emerging concept
of the premetastatic niche (185, 186). New findings
obtained with these tumor models include the capacity
of PDGF-BB, among other factors, to induce the forma-
tion of intratumor lymphatic vessels; that ability was
highlighted by several experiments including subcuta-
neous coinjection of human MCF7 cells and tumor-
associated fibroblasts (187). A murine dorsal chamber
model was also used to examine the lymphatic network
of the skin. In this model, Vegf-C–overexpressing cells
recruited functional lymphatic vessels within the cham-
ber, as assessed by Evans blue drainage (188).
Transgenic (Ripvegf-C) mice, which express Vegf-C
specifically in pancreatic  cells, were generated.
They develop a lymphatic network around those 
cells. These mice were crossed with a second trans-
genic (Rip1Tag2) strain that is known to develop
nonmetastatic pancreatic -cell tumors (189). These
double-transgenic mice exhibited Vegf-C–induced
lymphangiogenesis around the -cell tumors and
developed metastases to pancreatic and regional
lymph nodes (190). Furthermore, the loss of neural
adhesion molecule up-regulated the expression of
lymphangiogenic factors and increased lymphangio-
genesis, features that make this model a valuable tool
resembling endogenous tumor lymphangiogenesis
and lymph-node metastasis in immunocompetent
mice (191). This model highlighted the contribution
of integrin-1 to lymphangiogenesis (192).
Kaposi’s sarcoma is a skin cancer associated with
human herpesvirus-8 (HHV8), but its precise origin
remains controversial. Kaposi’s sarcoma expresses lym-
phatic markers, like podoplanin, VEGFR-3, and Prox-1,
and the plasma levels of lymphangiogenic molecules
are elevated in patients with such lesions (193, 194).
Blood vascular endothelial cells infected with Kaposi’s
sarcoma-associated HHV8 seem to undergo lymphatic
reprogramming (195). Symptoms include edema of the
lower extremities that is treated with lymphedema
therapy (196). Thus, this tumor may help to unravel
some molecular mechanisms of a new lymphatic-asso-
ciated pathology.
CONCLUSIONS
The lymphatic vessel system is an emerging field of
research. It has long been overshadowed by research on
angiogenesis because of the lack of markers to identify
and distinguish lymphatic and blood endothelial cells.
These tools are now available but the lymphatic circu-
lation remains difficult to study because of the absence
of appropriate culture models. These difficulties were
overcome partially during the past few years by the
development and validation of various 2-D and 3-D
culture systems, and novel in vivo models in rodents
and small animals. These new experimental models
contributed to the rapid expansion of our knowledge
on the mechanisms underlying lymphatic development
and the diseases associated with lymphatic dysfunction.
More information is still needed concerning the dis-
crimination of the direct effects on lymphangiogenesis
and inflammation-induced lymphangiogenesis, as both
events are very closely related (Fig. 2). It is demon-
strated that inflammatory cells can stimulate LECs by
growth factor secretion and by a transdifferentiation
of macrophages (168). The understanding of the
molecular pathways that regulate lymphatic network
formation, mostly in pathological conditions, and the
discrimination between those that act directly on
lymphatic endothelial cells and those modulating the
inflammatory process are mandatory to pave the way
to the development of new therapies for cancers,
lymphedemas, and inflammation-related diseases
(e.g., psoriasis, graft rejection).
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